| P/E (FY) | — | Sales (TTM) | €174.7M |
| Earnings (TTM) | — | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | — | Trading Days | 1290 |
| 52W High | 12.25 |
| 52W Low | 4.75 |
| % Off High | −58.69% |
| YTD | −42.63% | 1Y | −33.51% |
| 3Y | −66.36% | 5Y | −81.96% |
| Since incept. (ann.) | −28.77% |
| Ann. Volatility (1Y) | 72.69% | Ann. Volatility (3Y) | 64.23% |
| Sharpe (1Y) | −0.18 | Sharpe (3Y) | −0.23 |
| Max Drawdown (1Y) | −60.82% | Max Drawdown (3Y) | −75.79% |
| Beta (3Y, vs SPY) | 0.56 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| AMGN | AMGEN INC | $212.16B | 27.6 |
| GILD | GILEAD SCIENCES, INC. | $166.77B | 19.8 |
| RVMD | Revolution Medicines, Inc. | $39.09B | — |
| BIIB | BIOGEN INC. | $30.36B | 23.4 |
| MRNA | Moderna, Inc. | $22.14B | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $18.38B | 39.1 |
| EXEL | EXELIXIS, INC. | $14.20B | 20.3 |
| TECH | BIO-TECHNE Corp | $11.28B | 156.7 |
| KRYS | Krystal Biotech, Inc. | $10.74B | 53.3 |
| HALO | HALOZYME THERAPEUTICS, INC. | $9.90B | 32.6 |
| QGEN | QIAGEN N.V. | $9.17B | — |
| KYMR | Kymera Therapeutics, Inc. | $8.73B |
